Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | NPY1R | P25929 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996758 | 1.00 | RECQL (0.47) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1996759 | 1.00 | RECQL (0.47) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991766 | 0.86 | NPY1R (0.40) | ALDH1A1HTR2ANPY1RHTR2C | |
| SCHEMBL1991769 | 0.86 | NPY1R (0.40) | ALDH1A1HTR2ANPY1RHTR2C | |
| SCHEMBL1991767 | 0.86 | NPY1R (0.40) | ALDH1A1HTR2ANPY1RHTR2C | |
| SCHEMBL1998303 | 0.86 | RECQL (0.53) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991434 | 0.85 | L3MBTL1 (0.44) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991437 | 0.85 | L3MBTL1 (0.44) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991515 | 0.84 | RECQL (0.55) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1998943 | 0.83 | RECQL (0.50) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | RECQL 3604/4885SMN1; SMN2 2548/4885ALDH1A1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.